Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

PW-0787, a novel potent and brain-penetrant GPR52 agonist for neuropsychiatric disorders

Jan. 15, 2021

Chinese approval of Rykindo for schizophrenia and psychotic states

Jan. 15, 2021

Japanese researchers propose Lister hooded rats as a new model of ADHD

Jan. 15, 2021

Binding of NAD+ to the ARM domain in SARM1 self-inhibits SARM1 to avoid axonal degeneration

Jan. 15, 2021

Chi3l1/YKL-40 as therapeutic target to slow the progression of AD

Jan. 15, 2021

Daiichi reports phase I/II data on DS-5141 for Duchenne muscular dystrophy

Jan. 14, 2021

AAV9-cTuberin extends survival and reduces brain pathology in vivo

Jan. 14, 2021

OLT-1177 rescues cognitive impairment in a mouse model of AD

Jan. 14, 2021

Eisai presents new EphA4-targeting antibodies for AD

Jan. 14, 2021

NMD Pharma ApS patents new ClC-1 blockers

Jan. 14, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...